Login / Signup

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.

Dominik DannehlTobias EnglerLéa Louise VolmerChristian Martin TegelerJulia FusshoellerEmma GabryschKenneth EisslerAnna SellerEva-Maria GrischkeMarkus HahnInes GruberFabienne SchochterKerstin PfisterKristina VeselinovicElena LeinertBrigitte RackVisnja FinkWolfgang JanniSara Yvonne BruckerAndreas Daniel HartkopfHenning Schäffler
Published in: Cancers (2023)
Approximately one in ten patients with HR+/HER2-, and half of the patients with TNBC, meet the high-risk criteria according to OlympiA. Half of these patients do not meet the criteria for hereditary cancer testing and should therefore be tested for the presence of gBRCA1/2 mutations, irrespective of their own or family cancer history. The overall number of patients with early breast cancer benefiting from olaparib needs to be investigated in future studies.
Keyphrases